Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function
Sponsor: Pfizer
Summary
The purpose of the study is to look at how the body processes a study medicine called vepdegestrant in participants with loss of liver function relative to people with normal liver function. This study is seeking participants who are: * females who cannot have children or males * between 18 and 70 years of age * weigh more than 50 Kilograms (110 pounds) * either healthy with normal liver function or have loss of liver function All participants in this study will take one dose of vepdegestrant by mouth. This study looks at how the medicine is changed and removed from the body after being taken by the participants. The amount of vepdegestrant in participants with loss of liver function will be compared to the amount of vepdegestrant in participants with normal liver function. All participants will stay at the study clinic for about 11 days and 10 nights.
Official title: A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY TO COMPARE THE PHARMACOKINETICS OF VEPDEGESTRANT (PF-07850327) IN ADULT PARTICIPANTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT RELATIVE TO HEALTHY PARTICIPANTS WITH NORMAL HEPATIC FUNCTION
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2025-11-18
Completion Date
2026-12-23
Last Updated
2026-04-03
Healthy Volunteers
Yes
Conditions
Interventions
vepdegestrant
Vepdegestrant administered as a single oral 200 mg dose
Locations (4)
Clinical Pharmacology of Miami
Miami, Florida, United States
Floridian Clinical Research, LLC
Miami Lakes, Florida, United States
Orlando Clinical Research Center
Orlando, Florida, United States
Genesis Clinical Research, LLC
Tampa, Florida, United States